EMEA-002869-PIP01-21
Key facts
| Active substance |
Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0144/2022
|
| PIP number |
EMEA-002869-PIP01-21
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of pandemic influenza
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Seqirus Netherlands B.V.
E-mail: seqirus.clinicaltrials@seqirus.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|